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Abstract 23 
Virus infection of humans and livestock can be devastating for individuals and populations, 24 
sometimes resulting in large economic and societal impact. Prevention of virus disease by 25 
vaccination or anti-viral agents is difficult to achieve. A notable exception was the 26 
eradication of human smallpox by vaccination over 30 years ago. Today, humans and 27 
animals remain susceptible to poxvirus infections, including zoonotic poxvirus transmission. 28 
Here we identified a small molecule, bisbenzimide (bisbenzimidazole) and its derivatives, 29 
as potent agents against prototypic poxvirus infection in cell culture. We show that 30 
bisbenzimide derivatives, which preferentially bind the minor groove of double stranded 31 
DNA, inhibit vaccinia virus infection by blocking viral DNA replication and abrogating post-32 
replicative intermediate and late gene transcription. The bisbenzimide derivatives are 33 
potent against vaccinia virus and other poxviruses but ineffective against a range of other 34 
DNA and RNA viruses. The bisbenzimide derivatives are the first inhibitors of-their-class, 35 
which appear to directly target the viral genome without affecting cell viability.  36 
 37 
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Importance 44 
Smallpox was one of the most devastating diseases in human history until it was 45 
eradicated by a worldwide vaccination campaign. Due to discontinuation of routine 46 
vaccination more than 30 years ago, the majority of today’s human population remains 47 
susceptible to infection with poxviruses. Here we present a family of bisbenzimide 48 
(bisbenzimidazole) derivatives, known as Hoechst nuclear stains, with high potency against 49 
poxvirus infection. Results from a variety of assays used to dissect the poxvirus lifecycle 50 
demonstrate that bisbenzimides inhibit viral gene expression and genome replication. 51 
These findings can lead to the development of novel antiviral drugs that target viral 52 
genomes and blocking viral replication.  53 
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Introduction 54 
Viral infections are difficult to treat and prevent. Underlying technical reasons, such as 55 
diagnosis and viral persistence, viruses occur in large numbers, are genetically adaptable 56 
to environmental pressure, and highly dependent on their hosts (1-3). This makes it 57 
challenging to treat virus infections with compounds that target viral factors such as 58 
enzymes or structural proteins. Compounds directed against host factors required for 59 
infection potentially endanger the host, although there is emerging evidence that clinically 60 
approved anti-cancer agents have significant efficacy against viruses in post-exposure 61 
regimens (4). 62 
Today’s world population has become susceptible to poxvirus infection anew, after the 63 
discontinuation of smallpox vaccination over 30 years ago. Notable poxvirus cases include 64 
variola virus, the causative agent of smallpox, which despite eradication is ranked as a 65 
“category A pathogen” by the US National Institute of Allergy and Infectious Diseases. 66 
Further agents include vaccinia virus Cantalago and cowpox viruses which are contracted 67 
from infected animals and can cause fever and lesions (5-9), and monkeypox, which has a 68 
mortality rate estimated around 10% (10) and was responsible for the 2003 poxvirus 69 
outbreak in the U.S. (11, 12). 70 
There are few current treatment options against orthopoxvirus infections. These include 71 
live attenuated vaccinia virus (VACV)-based vaccines, Dryvax and ACAM2000, which can 72 
have some adverse effects including fever, rash, encephalitis and in rare cases 73 
(1:1,000,000) death (13, 14). Small molecule compounds against orthopoxvirus infections 74 
include Cidofovir, a nucleotide analog targeting the viral DNA polymerase (15), and ST-246 75 
(tecovirimat, TPOXX), the most promising anti-poxvirus drug, that inhibits virus cell-to-cell 76 
spread (16-18). For both Cidofovir and ST-246, poxvirus resistance has been reported (16, 77 
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19, 20). Remarkably, a single point mutation within the viral genome is sufficient to give 78 
rise to ST-246-resistance (16). In the face of a limited number of anti-poxvirus drugs there 79 
is an obvious need for novel antivirals directed against poxviruses. 80 
Targeting of the viral replication machinery by antivirals has been successfully employed 81 
against RNA and DNA viruses (15, 21-24). Inhibition of viral polymerases and helicases is 82 
effective as this strategy leads to sustained inhibition of genome replication thereby slowing 83 
the emergence of drug resistant mutations. To date, direct targeting of viral genomes by 84 
anti-viral agents has not been reported.  85 
Bisbenzimides are a class of fluorescent dyes that bind within the minor groove of double 86 
stranded DNA (dsDNA) preferentially to AT rich regions (25-29). These compounds have 87 
been used to drive pro-apoptotic and cytostatic activity in cancer cells (30, 31). In addition, 88 
bisbenzimide derivatives have been reported to indirectly modulate mammalian and 89 
bacterial topoisomerase I and II activity (32-35). Yet their application as antiviral agents has 90 
not been explored. 91 
Here, we present evidence that a set of bisbenzimide derivatives, which are commonly 92 
known as Hoechst compounds (29, 36-38), display potent anti-poxvirus activity far 93 
separated from cell toxicity. Dissection of poxvirus temporal gene expression, uncoating, 94 
genome replication and virus yield indicates that bisbenzimide-mediated anti-poxvirus 95 
activity occurs through inhibition of viral intermediate and late gene transcription as well as 96 
genome replication. 97 
 98 
 99 
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 6 
Results 100 
Bisbenzimides inhibit VACV infection  101 
To determine if bisbenzimides have antiviral activity against VACV we tested the ability of 102 
three different bisbenzimides to inhibit viral plaque formation assays, Hoechst 33342 (H4), 103 
Hoechst 33258 (H5), and Hoechst 34580 (H8) (Fig. 1A). Confluent monolayers of green 104 
monkey kidney (BSC40) cells were infected with serial dilutions of VACV strain Western 105 
Reserve (WR) which expresses EGFP from an early/late promoter (WR E/L EGFP) in the 106 
presence or absence of H4, H5 or H8. A known inhibitor of VACV DNA replication, cytosine 107 
arabinoside (AraC) (39, 40), served as a positive control in these experiments. At 24 h post 108 
infection (hpi) plates were imaged for nuclei indicating cell numbers, and GFP expression, 109 
a surrogate for infection (Fig. 1B). The total cell number and the number of infected cells 110 
were quantified using Plaque 2.0 (41) (Fig. 2). The H compounds displayed no apparent 111 
cell toxicity, with the exception of H4, and to a low extent H8 at the highest concentration 112 
tested of 20 µM. With each H compound, dose dependent inhibition of VACV infection was 113 
observed. H4 was the most potent compound, causing a complete block of VACV infection 114 
at 2µM regardless of virus concentration. H5 and H8 were less effective, both reaching 115 
complete inhibition at 20µM (Fig. 2). These effects were not specific to BSC40 cells, since 116 
similar results were obtained in L929 mouse fibroblasts (data not shown). The data show 117 
that bisbenzimides H4, H5, and H8 exert potent inhibitory activity against VACV infection 118 
with little cell toxicity when used at low µM concentrations.  119 
Bisbenzimides block intermediate and late but not early viral gene expression 120 
We next tested the impact of the most potent early/late gene expression inhibitor (H4) and 121 
the least toxic compound (H5) on early and late viral gene expression. VACV gene 122 
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 7 
expression occurs in three temporal stages, early, intermediate, and late. Early gene 123 
expression (EGE) occurs prior to DNA replication while intermediate gene expression (IGE) 124 
and late gene expression (LGE) requires DNA replication.  125 
BSC40 or HeLa cells were pretreated with H4 or H5 and infected with recombinant VACVs 126 
encoding EGFP under the control of an early (WR E EGFP) or a late (WR L EGFP) viral 127 
promoter. Cells treated with cycloheximide (CHX) and AraC served as positive controls for 128 
inhibition of EGE and LGE, respectively (Fig. 3). Infection was quantified by flow cytometry 129 
8 hpi. In BSC40 cells H4-treatment inhibited EGE up to 42% at 20µM, and completely 130 
blocked LGE at 800nM and above. H5 on the other hand did not inhibit EGE at any of the 131 
tested concentrations, but showed a dose-dependent inhibition of LGE of up to 90% from 132 
2µM to 20µM (Fig. 3A). In HeLa cells the trend of inhibition by H4 and H5 was similar but 133 
the compounds were more potent than in BSC40 cells with H4 resulting in complete 134 
inhibition of EGE at 4µM and LGE at 200nM, and H5 showing no impact on EGE, but 135 
inhibiting LGE by 100% at 4µM (Fig. 3B).  136 
The half maximum (EC50) and maximum (EC90) effective concentration for inhibition of 137 
EGE, IGE, and LGE were determined for H4 (Fig. 3C). HeLa cells were pre-treated with 138 
various concentrations of H4 and infected with WR E EGFP, WR I EGFP, or WR L EGFP 139 
viruses. Consistent with the date in Figure 2, the EC50 of H4 for EGE was 800nM and the 140 
EC90 1.6µM (Fig. 3C; blue line). H4 was even more effective against IGE and LGE with 141 
EC50 inhibition of IGE or LGE at 20nM, and EC90 at 80nM (Fig. 3C; green and red lines). 142 
These results show that the bisbenzimide H4 is an effective inhibitor of VACV IGE and 143 
LGE at nM concentrations.  144 
H4 blocks VACV plaque formation and reduces viral yield 145 
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 8 
Given the potent effect of H4 on IGE and LGE, we next assessed the ability of H4 to inhibit 146 
plaque formation and produce progeny. For plaque formation, monolayers of HeLa cells 147 
were infected with 150 plaque forming units (pfu) of VACV in the absence (NoT) or 148 
presence of 20nM or 80nM H4. At 72 hpi monolayers were assessed for plaque formation 149 
by staining the residual cells with crystal violet (Fig. 4A). In the presence of 20nM H4 both 150 
the size and number of plaques were strongly reduced, with a few small plaques detected. 151 
At 80nM H4 no visible plaques were visible. 152 
Next we assessed the impact of H4 on virus production in HeLa cells. In the presence of 153 
20nM H4 the number of infectious particles was reduced by 1.5 logs at 24 hpi. In the 154 
presence of 80nM H4, virus production was reduced by 4 logs relative to the 24 h yield in 155 
untreated cells (Fig. 4B). The results show that H4 effectively blocked VACV plaque 156 
formation and the production of infectious particles, even over extended periods (72 h) of 157 
incubation.  158 
H4 targets an early stage of VACV infection 159 
To address the stage of the virus lifecycle blocked by H4 we conducted add-in or wash-out 160 
experiments with H4 at different times of infection. When 80nM H4 was added as early as 161 
6 hpi, virus yield was reduced by 90% compared to no drug treated cells (Fig. 4C). 162 
Addition of H4 at 9 hpi gave a 50% reduction, and addition at 12 hpi had no impact on virus 163 
yield (Fig. 4C). In wash-out experiments only early washout of H4, for example at 30 or 90 164 
min pi, partially rescued virus yield, whereas washout at later times essentially had no 165 
rescue effects (Fig. 4D). These results indicated that H4 is most effective during early 166 
stages of infection.  167 
Pretreatment of purified VACV virions with H4 does not impact infectivity 168 
 o
n
 July 3, 2017 by CLAIRE HEBBLETHW
AITHE
http://jvi.asm.org/
D
ow
nloaded from
 
 9 
Remarkably H4 had little impact on EGE but diminished virus yield at early infection times 169 
when events such as EGE occur. To resolve this puzzling notion, we tested if H4 directly 170 
affected the infectivity of virions. WR E EGFP and WR L EGFP viruses were pre-incubated 171 
with H4 at 20nM (EC50) or 80nM (EC90), extensively washed to remove residual 172 
bisbenzimide, and added to HeLa cells. Cells were harvested and infection was analyzed 173 
by flow cytometry 8 hpi (Fig. 4E). Results showed that pre-incubation of virions with H4 had 174 
no significant impact on either EGE or LGE. To confirm these results a range of WR E/L 175 
EGFP virus concentrations were pre-incubated for various times with 2µM H4, a 176 
concentration which completely blocked EGE and LGE in HeLa cells (see Fig. 3B and C). 177 
Untreated and pre-treated virions were washed extensively before addition to cells. After 178 
24 h, infection was quantified using the microscopy-based Plaque2.0 assay (Fig. 4F). As 179 
expected infection was dose-dependent, yet even at 2µM H4, no inhibition of VACV 180 
infection was observed. These results show that H4 does not directly impact the infectivity 181 
of extracellular virions but rather acts on a critical intracellular stage of the VACV lifecycle.  182 
H4 treatment does not impact VACV genome uncoating  183 
Given that H4 had no impact on EGE but effectively blocked IGE and LGE we assessed 184 
genome uncoating [reviewed in (42, 43)], as it is a pre-requisite for VACV genome 185 
replication and subsequent IGE and LGE. Incoming VACV genomes released into the 186 
cytoplasm, termed pre-replication sites, can be visualized by immunofluorescence directed 187 
against the viral single-stranded DNA binding protein I3, or with click-chemistry based 188 
detection of single virus genomes (44-48).  189 
Here we used I3 staining to test the influence of H4 on VACV pre-replication site formation, 190 
HeLa cells were infected in the presence of 20nM, 80nM or 200nM H4, fixed at 5 hpi and 191 
stained for I3 (Fig. 5A). AraC, which blocks viral replication post uncoating, and CHX, 192 
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which blocks uncoating by inhibiting the synthesis of the VACV uncoating factor (47) were 193 
included as controls. As expected CHX prevented the formation of pre-replication sites, 194 
while AraC did not affect the number of I3 puncta. H4 did not affect the number of I3-195 
positive pre-replication sites (Fig. 5B). These results show that H4 does not affect VACV 196 
genome uncoating even at concentrations above those that inhibit IGE and LGE. 197 
High concentrations of H4 inhibit VACV DNA replication 198 
We next tested the impact of H4 on VACV DNA replication site formation. Cells were 199 
infected in the presence of 20nM, 80nM, or 200nM H4 and assessed for replication site 200 
formation by staining with 4',6-diamidino-2-phenylindole (DAPI) at 8 hpi. As expected, 201 
untreated cells contained large cytoplasmic VACV replication sites while AraC treated cells 202 
had none (Fig. 6A). The replication sites in H4- treated cells showed phenotypic differences 203 
from control infections. At 20nM the replication sites appeared slightly smaller and more 204 
diffuse, and at 80nM and 200nM the size of the replication sites was reduced and many 205 
small DAPI positive puncta were seen (Fig. 6A). When the number of cells containing 206 
replication sites was quantified, without accounting for their size or number, treatment with 207 
20nM or 80nM H4 showed a 14.9 % and 20.7 % decrease respectively, while treatment 208 
with 200nM H4 decreased cells containing replication sites by 48.2 % (Fig. 6B). We noticed 209 
that the replication sites seen in the presence of 200nM H4 were larger than the pre-210 
replication sites seen in the presence of AraC (Fig. 5A). This suggested that H4 did not 211 
block DNA replication initiation, but rather acted after the onset of replication.  212 
To assess the impact of H4 on on-going replication we used 5-ethynyl-20-deoxyuridine 213 
(EdU) and click chemistry labeling (48). Cells were infected in the absence or presence of 214 
20nM, 80nM, or 200nM H4 and the incorporation of EdU into viral replication sites was 215 
assessed at 8 hpi (Fig. 6C). Untreated cells displayed numerous bright EdU-positive 216 
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replication sites. At 20nM and 80nM the replication sites appeared less numerous but 217 
brighter, while at 200nM small replication sites with little EdU incorporation were seen (Fig. 218 
6C). Quantification of the intensity of EdU/cell confirmed that nucleoside incorporation into 219 
viral replication sites was slightly reduced at 20nM and 80nM H4, and strongly reduced in 220 
the presence of 200nM H4 to the levels seen in the presence of AraC (Fig. 6D).  221 
H4 blocks VACV DNA replication, IGE and LGE in a dose dependent fashion 222 
Given the considerable size of the viral replication sites seen in the presence of 20nM and 223 
80nM H4, we performed qPCR to quantify VACV DNA synthesis in the presence of H4 224 
(49). Total DNA was extracted from cells infected with VACV at 8 hpi, and the amount of 225 
viral DNA quantified. While AraC blocked DNA accumulation as expected, no defect in viral 226 
DNA content was seen in the presence of 20nM H4, and a modest decrease of 11% was 227 
observed at 80nM H4 (Fig. 6E). VACV DNA accumulation was reduced by 88% in the 228 
presence of 200nM H4, consistent with the small replication site phenotype observed in 229 
Figure 6.  230 
As VACV IGE and LGE occur after DNA replication it was surprising to find that DNA 231 
accumulation was largely unimpeded in the presence of 20nM and 80nM H4, the 232 
respective EC50 and EC90 against VACV infection. We reasoned that H4 may be inhibiting 233 
transcription of VACV IGE and LGE at these low concentrations. Using quantitative reverse 234 
transcription PCR (RT-qPCR) we assessed the impact of H4 on the accumulation of viral 235 
early (J2), intermediate (G8), and late (F17) mRNAs (Fig. 6F). While H4 had little impact on 236 
early viral mRNA amounts, accumulation of intermediate mRNA was diminished by 72% 237 
and late by 48% at 20nM H4 (Fig. 6F). At 80nM and 200nM H4, intermediate mRNA 238 
accumulation was completely abrogated and late mRNA reduced by 88% and 76%, 239 
respectively. These results indicate that the bisbenzimide H4 impedes VACV infection by 240 
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inhibiting two stages of the virus lifecycle; at low levels (20nM and 80nM), H4 inhibits IG 241 
and LG transcription, and at elevated levels (200nM), it inhibits VACV DNA replication as 242 
well as IG and LG transcription.  243 
Poxvirus infection is acutely sensitive to the antiviral activity of H4  244 
Given the potent inhibitory effects of H4 on VACV transcription and replication we asked if 245 
H4 could inhibit infection by other poxviruses. We tested three different parapoxviruses: 246 
ORF-11, MRI-SCAB (50), and squirrelpox virus (SQPV) (51). For this, Foetal Lamb Skin 247 
cell monolayers were infected with these viruses in the presence of 20nM, 80nM, or 200nM 248 
H4. Cell monolayers were assessed for plaque formation at 3 days PI with VACV or ORF-249 
11, and 7 days with MRI-SCAB or SQPV. In the absence of H4 all viruses produced 250 
plaques, or in the case of SQPV destroyed the monolayer (Fig. 7A). Strikingly, treatment 251 
with H4 at 20nM, 80nM, or 200nM completely attenuated plaque formation by all the 252 
viruses (Fig. 7A). These results demonstrate that the bisbenzimides H4 is a broad range 253 
inhibitor of poxvirus infection across different genera.  254 
While we had shown previously that H4 did not affect plaque formation by human 255 
adenovirus (52), we wanted to test the impact of H4 on other viruses, Herpes simplex 256 
virus-1 (HSV) which replicates in the nucleus (53), and RNA viruses which replicate either 257 
in the nucleus (Influenza A virus, IAV), or the cytoplasm (Vesicular Stomatitis Virus, VSV; 258 
Semliki Forest Virus, SFV). When cells were infected with these viruses in the presence of 259 
20nM or 200nM H4, expression of GFP from reporter viruses was not significantly 260 
impacted regardless of the concentration used (Fig. 7B). We conclude that bisbenzimides 261 
are rather selective inhibitors against poxviruses and do not affect a broad range of 262 
unrelated viruses.  263 
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Discussion  264 
Bisbenzimides are a class of fluorescent dyes commonly used in flow cytometry and 265 
fluorescence microscopy to identify cell nuclei. Bisbenzimides stain DNA in the nucleus 266 
and cytoplasmic organelles, such as mitochondria and chloroplasts (36). Here we 267 
demonstrate that a range of bisbenzimides are potent inhibitors of poxvirus infection. We 268 
used a variety of virological assays to determine the stage of the VACV lifecycle impacted 269 
by H4, the most effective H derivative tested. We found that H4 did not inhibit infection by 270 
acting on extracellular viral particles, nor by targeting the early stages of the virus lifecycle, 271 
including EGE and DNA uncoating. Analysis of viral EG, IG, and LG transcription, DNA 272 
replication site formation, and viral DNA synthesis indicated that H4 blocked IG and LG 273 
transcription as well as DNA replication in a dose-dependent manner. H4 strongly inhibited 274 
the production of infectious VACV particles, and plaque formation was impeded in its 275 
presence.  276 
Our results indicate that the effectiveness of bisbenzimides against poxviruses correlates 277 
with the accessibility of the viral DNA to solutes. We found that the H compounds did not 278 
affect the infectivity of VACV particles when the particles were intact, that is when they 279 
were outside of cells. The compounds were effective after viral DNA was released from the 280 
capsid into the cytosol, where it is replicated. Consistent with this, the EC50 of H4 against 281 
EGE, which occurs when the viral core is largely intact, was 20-fold higher than the EC50 282 
for IGE and LGE, which only occurs from exposed viral DNA. EG transcription occurs 283 
within cytoplasmic viral cores prior to genome uncoating, while IG and LG transcription 284 
occur in the cytoplasm after viral genome replication (54). High concentrations of H4 could 285 
impact early gene expression during the activation of cytosolic cores, which expand when 286 
EG transcription [(55-57) and (58)]. We speculate that core expansion may lead to 287 
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increased accessibility of the VACV genomes within. That early, intermediate, and late 288 
VACV mRNAs are all translated in the cytoplasm on host ribosomes makes it unlikely that 289 
bisbenzimides impact translation of viral proteins. 290 
We noted that the inhibitory efficacy of the bisbenzimides correlated with their lipophilicity, 291 
H4>H8>H5 (Fig. 1A). Lipophilicity largely dictates the binding of bisbenzimides to double-292 
stranded DNA via hydrophobic interactions with adenosine-threonine (A=T) rich regions 293 
(25, 59, 60). Since poxviruses with differential genomic A=T content, that is VACV (67% 294 
A=T), ORFV (36% A=T), and SQPV (33% A=T) (61), display similar sensitivity to H4 it is 295 
unlikely that poxviruses are susceptible to bisbenzimides simply due to their high A=T 296 
content. It is more likely that the solute accessibility of the viral genome and the association 297 
of DNA binding proteins dictates susceptibility of the virus to the H compounds.  298 
Remarkably, despite their effectiveness against poxviruses the H-bisbenzimides tested had 299 
no effect on infection by other DNA viruses, such as adenovirus or herpesvirus. As 300 
opposed to poxviruses, herpesviruses and adenoviruses deliver their infectious incoming 301 
DNA genomes directly into the nucleus where they are transcribed and replicated (48, 53, 302 
62-64). It is possible that bisbenzimides do not efficiently bind to the nuclear DNA of 303 
adenovirus and herpes virus due to the spatial proximity of host DNA, which acts as an 304 
efficient local avidity trap for the bisbenzimides. In this scenario, bisbenzimides used at low 305 
nanomolar, non-toxic concentrations would be more likely to bind to host DNA than viral 306 
DNA.  307 
While selection of VACV variants resistant to the anti-poxvirus agents cidofovir or ST-246 308 
is readily possible (16, 65), we were unable to isolate a bisbenzimide-resistant VACV in up 309 
to 20 passages at different concentrations of H4 (data not shown). This is consistent with 310 
our finding that H4 targets at least two viral processes. Low concentrations of H4 inhibited 311 
 o
n
 July 3, 2017 by CLAIRE HEBBLETHW
AITHE
http://jvi.asm.org/
D
ow
nloaded from
 
 15 
IG and LG transcription, while higher concentrations of H4 also blocked viral DNA 312 
replication. IG and LG transcription inhibition at low H4 concentrations could occur since 313 
the intermediate and late promoters are AT-rich (66), and H4 preferentially binds to AT-rich 314 
dsDNA. The presence of small highly condensed viral DNA replication sites observed in 315 
the presence of high concentrations of H4, and the observation that VACV topoisomerase 316 
DNA unwinding activity is unaffected in vitro (data not shown) (67), suggests a model in 317 
which bisbenzimides block DNA replication by coating cytoplasmic VACV genomes. 318 
In sum, we show that bisbenzimide compounds are highly specific for inhibiting poxvirus 319 
infections at low apparent cytotoxicity. It is possible that the bisbenzimides tested here are 320 
also effective against divergent members of the nucleocytoplasmic large DNA viruses that 321 
replicate exclusively in the cytoplasm (68). Bisbenzimide compounds have been used in 322 
mice with potential antitumor effects (30), and were tested in a phase I-II advanced 323 
pancreatic carcinoma study in humans (69). Notably, in both cases bisbenzimides were 324 
well tolerated. While the in vivo efficacy of bisbenzimides against poxvirus infection has not 325 
been determined, the dual mechanism of inhibition, that is intermediate / late gene 326 
expression and viral DNA replication, appears to be a high barrier against the emergence 327 
of viral resistance. This makes it tempting to speculate that bisbenzimides may serve as 328 
attractive anti-poxvirus drugs, either alone or in combination with CMX001 and ST-246 329 
(70). 330 
Materials and Methods 331 
Cell Culture and Reagents 332 
All cells lines used were cultivated as monolayers at 37.0 °C and 5.0% CO2. Cells were 333 
cultured in Dulbecco’s Modified Eagle Medium (DMEM, GIBCO, Life Technologies, 334 
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Switzerland). HeLa (ATCC) and mouse subcutaneous areolar and adipose cells L929 335 
(ATCC) were cultivated in DMEM with the addition of 10% Fetal Bovine Serum (FBS, 336 
Sigma), 2mM GlutaMAX (Life Technologies) and 1% peneciline-streptomycine (Pen-Strep, 337 
Sigma). Cercopithecus aethiops kidney epithelial cells (BSC40, ATCC) were cultivated in 338 
DMEM with 10% FBS, 2mM GlutaMAX, 1% Non-essential amino acids mix (NEAA, Sigma) 339 
and 1mM sodium pyruvate (NaPyr, Sigma). HDFn human foreskin fibroblasts cell line 340 
(Invitrogen) was cultivated in DMEM containing 5% FBS. Foetal Lamb Skin cells were 341 
cultivated in Media 199 (Sigma) with 2 % glutamine, 0.16 % sodium hydrogen carbonate, 342 
10 % tryptose phosphate broth, and 10 % FBS. 343 
VACV and Parapoxvirus Strains and Virus Purification 344 
Vaccinia virus strain Western Reserve (VACV WR) (71) and International Health 345 
Department J (VACV IHD-J) (72) were used throughout. These strains were either wild 346 
type (WT) or transgenic containing early/late EGFP (E/L EGFP VACV WR, E/L EGFP 347 
VACV IHD-J), early EGFP (E EGFP VACV WR), intermediate EGFP (I EGFP VACV WR), 348 
late EGFP (L EGFP VACV WR). All VACV mature virions (MVs) were purified from 349 
cytoplasmic lysates by pelleting through a 36% sucrose cushion for 90 min at 18,000 x g. 350 
The virus pellet was resuspended in 10mM Tris pH 9.0 and subsequently banded on a 25 351 
to 40% sucrose gradient at 14,000 x g for 45 min. Following centrifugation, the viral band 352 
was collected by aspiration and concentrated by pelleting at 14,000 x g for 45 min. MVs 353 
were resuspended in 1mM Tris pH 9.0 and tittered for plaque forming units per milliliter 354 
(PFU/ml) as previously described (73). The parapoxvirus strains used include a tissue 355 
culture adapted strain, ORF-11, a non-adapted strain MRI-SCAB, and Squirrelpox (SQPV).  356 
IAV was obtained from Yohei Yamauchi, SFV and VSV were obtained from Giuseppe 357 
Balistreri, HSV-1 was obtained from Cornel Fraefel. 358 
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Inhibitors, Dyes, Antibodies and Plasmids 359 
Cycloheximide (CHX, Sigma) was used at 50µM, cytosine arabinosid (Cytarabine, Ara-C, 360 
Sigma) was used at 10µM. Bisbenzimides H4, H8 and H5 (Sigma) were dissolved in water 361 
and used as described in the respective experiments. Rabbit polyclonal anti-EGFP was 362 
used in 1:1000 dilution. Anti-I3 antibody (generous provided by Jakomine Krijnse Locker; 363 
Institute Pasteur) was used at 1:500. All secondary antibodies goat anti-rabbit-AF488 and 364 
goat anti-rabbit-AF594 (Invitrogen) were used at 1:1000. 365 
Plaque2.0 Assay 366 
BSC40 cells were cultivated as monolayers in 96-well imaging plates (Greiner Bio-One, 367 
Germany) and inoculated with a serial dilution of either E/L EGFP VACV WR or E/L EGFP 368 
VACV IHD-J. 1 hpi the inoculum was removed and replaced with medium (non-treated 369 
control) or a respective dilution of an experimental compound in the medium. 24 hpi plates 370 
were fixed with 4% PFA and stained with Hoechst nuclear stain. Plates were imaged using 371 
ImageXpress XL Micro epi-fluorescent high-throughput microscope (Molecular Devices, 372 
USA) with a 4x air objective (Nikon, Japan) in a tile mode allowing full well reconstruction. 373 
Image processing and analysis was performed using Plaque2.0 software (41) . Experiment 374 
was performed in three technical replicas (triplicate). 375 
Early, Intermediate and Late VACV Gene Expression Analysis 376 
HeLa or BSC40 cells in 24-well plates were infected with E EGFP VACV WR and L EGFP 377 
VACV WR at MOI 5 together with H4 in different concentrations. To quantify EGE or IGE 378 
and LGE cells were infected for six or eight hours, respectively. Cells were detached with 379 
0.05% Trypsin-EDTA and fixed in 4% formaldehyde for 15 minutes. After centrifugation at 380 
500 g for 5 min, the cell pellets were re-suspended in 400 µl FACS buffer. A BD Bioscience 381 
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FACSCalibur flow cytometer was used for analysis and 10,000 cells per condition were 382 
measured. 383 
Virus Titrations by Plaque Assay 384 
Viruses were diluted in the cell line appropriate media and 250µL or 500 µl of this virus 385 
dilution added to HeLa or Foetal Lamb Skin cell monolayers in 6-well plates. The plates 386 
were rocked every 15 minutes and after 1 hour, media was aspirated and cells fed with full 387 
media containing the indicated compound concentrations. The cells were then incubated at 388 
37 °C for 3, 4, or 7 days (as indicated) before staining with 0.1% crystal violet in 3.7% PFA. 389 
24 h Virus Yield  390 
HeLa cells in 12-well plates were infected at MOI 1 in presence of the compound. After 24 391 
h cells were collected, centrifuged, and the pellet re-suspended in 100µl 1mM Tris pH 9.0. 392 
Cells were freeze-thawed three times to lyse the cells and the virus solution subjected to 393 
serial titration to determine the pfu/ml. 394 
Add-in and Wash-out Assays 395 
HeLa cells were grown in 12-well plates and infected with WT VACV WR at MOI 1. For 396 
wash-out experiments, infection was performed in the presence of 80nM H4. At indicated 397 
time point the cells were washed five times with medium and infection allowed to proceed 398 
in the absence of compound. For add-in experiments, medium containing 80nM H4 was 399 
added to the cells at the indicated time points. For both, at 24 hpi, cells were collected and 400 
titered as above.  401 
Pre-treatment of Virus Particles with H4 402 
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Viruses expressing EGFP from early or late promoters were pre-incubated with 20nM or 403 
80nM H4 for the indicated times at room temperature. The virus particles were washed 404 
three times in media and used to infect HeLa cells. Similarly, to early and late gene 405 
profiling, infection was stopped after 6 to 8 hpi and infection analyzed by flow cytometry. 406 
Pre-replication Site Visualization 407 
HeLa cells were infected with WT VACV at MOI 10 in the presences of AraC and 20nM, 408 
80nM or 200nM H4. At 5 hpi cells were fixed, nuclei stained with Dapi and pre-replication 409 
sites visualized by immunofluorescence staining against VACV I3. Images were acquired 410 
by confocal microscopy and Max projections generated from 10 Z-stacks. The number of 411 
pre-replication sites/cell in the presence of 20nM, 80nM or 200nM H4 was determined by 412 
spot detection of the MaxIntProjections with a (Fiji: spots larger than 5 pixels). Cells treated 413 
with CHX alone served as controls for genome uncoating and replication site formation, 414 
respectively. 415 
Replication Site Formation 416 
HeLa cells were infected with WT VACV at MOI 5 in the presence of 20nM, 80nM or 417 
200nM H4. At 8hpi, cells were fixed and VACV replication sites visualized by staining with 418 
Dapi. The percentage of cells containing replication sites were quantified by manual 419 
counting due to the shape and size variation of replication sites under the various 420 
conditions. AraC sample served as a control for inhibition of DNA replication site formation. 421 
EdU Accumulation 422 
HeLa cells were infected with WT VACV at MOI 10. After 1h virus binding in DMEM, the 423 
media was changed to 10% DMEM containing 1µM EdU in the presence of absence of H4 424 
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(20 nM, 80 nM, or 200 nM). At 8 hpi cells were fixed with 4% PFA and stained using Click-425 
iT EdU Imaging kit (Thermo Scientific) and Hoechst to visualize cell nuclei. Cells were 426 
imaged using confocal microscopy and analyzed using CellProfiler/KNIME software. 427 
Briefly, the intensity of EdU staining per sample was determined after background 428 
subtraction and exclusion of nuclei by image segmentation.  429 
Viral DNA Quantification by qPCR 430 
HeLa cell monolayers were infected with WR (MOI 10) in the absence or presence of H4 431 
for 8 h. Total DNA was extracted using the Qiagen DNeasy Blood and Tissue Kit according 432 
to the manufacturer's instruction. Total DNA concentrations were assessed using a 433 
Nanodrop™ spectrophotometer and a portion of total DNA was used in qPCR assay using 434 
Mesa Blue qPCR MasterMix Plus for SYBR Assay system (Eurogentec) with following 435 
primers: C11R (5’-AAACACACACTGAGAAACAGCATAAA-3’ and 5'-436 
ACTATCGGCGAATGATCTGATTA-3’). Concentration of viral DNA was determined by 437 
plotting against a standard curve of VACV DNA from purified virions.  438 
Reverse Transcriptase-PCR 439 
HeLa cell monolayers were infected with WR (MOI 10) in the absence or presence of H4 440 
for 2, 4, or 8 h. Total RNA was harvested from infected cells using the Qiagen RNeasy kit 441 
according to manufacturer's instructions. Subsequently, 1 µl of total RNA was reverse-442 
transcribed into single-stranded cDNA with SuperScript-II reverse transcriptase (Thermo 443 
Fisher Scientific) and oligo(dT) primers. Amplification of J2 (early) from 2 h samples, G8 444 
(intermediate) from 4 h samples, F17 (late) from 8 h samples, and glyceraldehyde-3-445 
phosphate dehydrogenase (GAPDH) cDNA from all time points was performed by qPCR 446 
(Mesa Blue qPCR MasterMix Plus for SYBR Assay, Eurogentec) using primers specific for 447 
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VACV J2R (5′-TACGGAACGGGACTATGGAC-3′ and 5′-GTTTGCCATACGCTCACAGA-448 
3′), G8R (5’-AATGTAGACTCGACGGATGAGTTA-3’, 5’-449 
TCGTCATTATCCATTACGATTCTAGTT-3’), F17R (5’-ATTCTCATTTTGCATCTGCTC-3’, 450 
5’-AGCTACATTATCGCGATTAGC-3’), and GAPDH (5’ AAGGTCGGAGTCAACGGATTTG 451 
GT-3’ and 5’-ACAAAGTGGTCGTTGAGGGCAATG-3’). Viral mRNA Ct values are 452 
displayed as abundance normalized against GAPDH.  453 
Influenza A Virus, Semliki Forest Virus, Vesicular stomatitis Virus and Herpes 454 
Simplex Virus-1 infections 455 
EGFP expressing variants of the indicated viruses were used for these experiments. For 456 
each, HeLa cells were infected at an MOI of 5 in the presence of 20nM or 200nM of H4 and 457 
cells prepared for flow cytometry analysis between 6 and 8 hpi. 458 
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Figure Legends 647 
Figure 1. (A) The chemical structure, properties including partitioning coefficient (LogP) 648 
and compound information of the bisbenzimides used in this study. (B) Bisbenzimides (H4, 649 
H5, H8) block VACV replication in tissue culture. BSC40 cells were infected with a serial 650 
dilution of E/L EGFP VACV and treated with serial dilutions of H4, H5, H8 or AraC. Full well 651 
images show EGFP expressing infected cells color-coded by intensity (left panels). Nuclei 652 
were detected by staining with Hoechst (right panels). Experiments were performed in 653 
triplicate and representative images displayed. 654 
Figure 2. Quantification of infected EGFP expressing cells and total cell number (nuclei) 655 
from figure 1B. Grey bars indicate infection index and red boxes cell number for each 656 
condition tested. Experiments were performed in triplicate results displayed as mean ± SD. 657 
Figure 3. Bisbenzimides inhibit VACV intermediate and late gene expression. (A and B) 658 
BSC40 (A) or HeLa (B) cells were infected with WR E EGFP (gray bars) or WR L EGFP 659 
(black bars) VACV. Cells were scored for EGFP expression by flow cytometry and infected 660 
cells quantified relative to untreated cells. CHX or AraC served as controls for these 661 
experiments. (C) HeLa cells treated with various concentrations of H4 were infected with 662 
WR E EGFP (blue line), or WR I EGFP (green line), or WR L EGFP (red line) and the 663 
percentage of EGFP-positive infected cells quantified by flow cytometry. These values 664 
were fitted to dose response curves to estimate EC50 and EC90 values (dashed lines).  665 
Figure 4. H4 inhibits plaque formation, reduces virus yield, and blocks early VACV 666 
infection without impacting particle infectivity. (A) HeLa cells were infected with 150 pfu of 667 
WT VACV and infection allowed to proceed for 72h. The plates were stained with crystal 668 
violet to visualize plaques . (B) HeLa cells were infected with WT VACV (MOI 1). 24 hpi 669 
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cells were harvested, lysed and virus yield determined by titration and plaque formation. 670 
(C) HeLa cells were infected with WT virus (MOI 1) and 80nM H4 added at the indicated 671 
time points. A sample subjected to AraC addition at 6hpi was included as a positive control 672 
for inhibition. Cells were harvested 24 hpi and virus yield determined for each sample by 673 
serial dilution plaque assay. (D) HeLa cells were infected with WT virus (MOI 1) in the 674 
presence of 80nM H4. At the indicated time points, cells were washed and infection 675 
allowed to proceed. A sample subjected to AraC washout at 6hpi was included as a 676 
positive control for inhibition. At 24 hpi virus yield was determined for each sample by serial 677 
dilution plaque assay. (E) WR E EGFP (black bars) or WR L EGFP (white bars) virions 678 
were pre-incubated with 20nM or 80nM H4 for 30min at room temperature. Virus particles 679 
were washed three times and used to infect HeLa cells. Samples were analyzed by flow 680 
cytometry for infected EGFP-positive cells at 6 hpi (early) and 8 hpi (late). (F) WR E/L 681 
EGFP virions were pre-incubated with 2µM H4 for 2, 3 or 4 hours. Virions were washed 682 
and used to infect HeLa cells prior to fixation and analysis by plaque 2.0 for total nuclei and 683 
EGFP-positive infected cells. (A-F) All experiments were performed in triplicate and 684 
representative images shown (A) or results displayed as means ± SD (B-F). 685 
Figure 5. H4 does not impact viral genome uncoating (A) HeLa cells were infected with WT 686 
VACV (MOI 10) in the presence of 20nM, 80nM or 200nM H4 and AraC. Pre-replication 687 
sites were visualized by immunofluorescence staining against I3 followed by confocal 688 
microscopy. CHX or AraC served as controls for uncoating and replication, respectively. 689 
(B) Quantification of pre-replication sites per cell from A. (A and B) Experiments were 690 
performed in triplicate, representative images displayed, and results displayed as mean ± 691 
SEM. Scale bar = 10 μm. 692 
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Figure 6. H4 attenuates VACV IG/LG transcription and DNA replication in a dose-693 
dependent fashion. (A) HeLa cells were infected (MOI 10) in the presence of 20nM, 80nM 694 
or 200nM H4. At 8 hpi cells were fixed and stained with Dapi and imaged by confocal 695 
microscopy. Scale bar = 10 μm. (B) The number of cells with cytoplasmic replication sites 696 
was quantified per condition. AraC served as a control for inhibition of DNA replication site 697 
formation. (C) HeLa cells were infected (MOI 10) in the presence of 20nM, 80nM or 200nM 698 
H4 and EdU. At 8 hpi EdU incorporation was detected by Click-iT EdU Imaging kit followed 699 
by confocal microscopy. Scale bar = 10 μm. (D) The total intensity of EdU incorporation 700 
into replication sites was quantified and displayed as the mean ± SD. (E) The amount of 701 
viral DNA from cells infected in the absence or presence of H4 at different concentrations 702 
was quantified by qPCR at 8 hpi. AraC served as a control for inhibition of DNA replication 703 
(F) The levels of early (J2), intermediate (G8), and late (F17) viral mRNA from infected 704 
HeLa cells were quantified by RT-qPRC. Cells were infected in the absence of presence of 705 
various concentrations of H4 and RT performed at 2 hpi for J2, 4 hpi for G8, and 8 hpi for 706 
F17. Results are displayed as the average abundance normalized to untreated samples. 707 
(A-D) All experiments were performed in triplicate and representative images (A and C) or 708 
means ± SD (B, D-F) displayed.  709 
Figure 7. Poxviruses are acutely sensitive to H4 inhibitory activity. (A) Foetal Lamb Skin 710 
cell monolayers were infected with VACV or ORF-11 (100 pfu), MRI-SCAB (500 pfu), or 711 
Squirrelpox (1000 pfu). Cells were fixed and plaques visualized by crystal violet staining at 712 
3 days (VACV), 4 days (ORF-11), or 7 days (MRI-SCAB and SQPV). Experiments were 713 
performed in triplicate and representative images shown (B) HeLa cells were infected with 714 
EGFP-expressing variants of VACV WR, Herpes Simplex Virus 1 (HSV-1), Influenza A 715 
virus (IAV), Vesicular Stomatitis Virus (VSV), or Semliki Forest Virus (SFV). For each, 716 
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infection was allowed to proceed for 6-8 h after which cells were analyzed for EGFP 717 
expression by flow cytometry. Experiments were performed in triplicate and the percent 718 
infection relative to untreated controls displayed as mean ± SD. 719 
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